triptorelin pamoate

triptorelin pamoate

Decapeptyl SR (UK), Gonapeptyl Depot (UK), Trelstar Depot, Trelstar LA

Pharmacologic class: Synthetic agonist analog of luteinizing hormone-releasing hormone (LHRH)

Therapeutic class: Antineoplastic

Pregnancy risk category X


Initially causes surge in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels. After several weeks of therapy, LH and FSH secretion decrease, causing sustained testosterone reduction equivalent to pharmacologic castration.


Microgranules for injection (lyophilized): 3.75 mg (depot), 11.25 mg (long-acting), 22.5 mg (long-acting)

Indications and dosages

Palliative treatment of advanced prostate cancer

Adults: 3.75 mg (depot) I.M. monthly as a single injection or 11.25 mg (long-acting) I.M. q 12 weeks as a single injection or 22.5 mg (long-acting) I.M. q 24 weeks

Off-label uses

• Infertility

• Endometriosis

• Uterine fibroids

• Precocious puberty


• Hypersensitivity to drug, LHRH, or other LHRH agonists

• Pregnancy

• Women of childbearing potential


Use cautiously in:

• renal insufficiency

• prostate cancer with impending spinal cord compression or severe urinary tract disorder

• breastfeeding patients (use not recommended).


• Reconstitute with 2 ml of sterile water for injection, using accompanying syringe (don't use other diluents). Add syringe contents to vial containing particles; shake well. Withdraw vial contents and inject I.M. immediately.

• Inject deep I.M. into either buttock. Rotate injection sites.

Keep epinephrine and emergency equipment at hand in case of anaphylactic reaction.

Adverse reactions

CNS: insomnia, dizziness, headache, emotional lability, fatigue, stroke

CV: hypertension, increased risk of myocardial infarction and sudden cardiac death

GI: vomiting, diarrhea

GU: urinary retention, urinary tract infection, gynecomastia, erectile dysfunction, testicular atrophy

Hematologic: anemia

Metabolic: hyperglycemia

Musculoskeletal: skeletal or leg pain

Skin: pruritus

Other: leg edema, temporary worsening of disease, edema, hot flashes, pain at injection site, hypersensitivity reactions including anaphylaxis


Drug-diagnostic tests. Hemoglobin: decreased value

Pituitary-gonadal function tests: misleading results (with continuous or long-term use)

Serum glucose: increased

Patient monitoring

• Monitor serum testosterone and prostate-specific antigen levels periodically to assess drug efficacy.

Monitor patient for signs and symptoms suggestive of cardiovascular disease and manage as appropriate.

Patient teaching

• Explain drug therapy to patient. Stress need for follow-up laboratory tests.

• Tell patient prostate cancer symptoms may worsen during first few weeks of therapy.

• Instruct patient to monitor weight and report sudden weight gain or leg swelling.

• Advise female patient to tell prescriber before starting therapy if she is or plans to become pregnant. Caution her not to breastfeed during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

References in periodicals archive ?
It was reported yesterday that the collaboration is aimed at providing triptorelin pamoate 3.
gov identifier: NC 7-01161563) assessed patients' and clinicians' perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male patients with advanced prostate cancer.
Leuprolide acetate (Eligard[R]) and triptorelin pamoate (Trelstar[R]) are two such GnRH agonists indicated for the palliative treatment of advanced prostate cancer.
Looking at the use of triptorelin pamoate (Trelstar), goserelin acetate implant (Zoladex), and leuprolide acetate suspension (Lupron, Eligard), the OIG found that physicians favored the use of the more expensive drugs while the least costly alternative policies were in place, but that their use was slowly declining.
Looking at the use of triptorelin pamoate (Trelstar), goserelin acetate implant (Zoladex), and leuprolide acetate suspension (Lupron, Eligard), the OIG found that physicians favored use of the more expensive drugs while the least costly alternative policies were in place but that their use was slowly declining.
Products successfully registered and launched include oxaliplatin for advanced colorectal cancer and triptorelin pamoate for prostate cancer, both market leaders in their therapeutic areas.
The firm aims to apply for the addition to the label of the subcutaneous route, alongside the intramuscular route, of triptorelin pamoate 11.
The trial assessed the efficacy, safety and local tolerability of a three-month triptorelin pamoate (11.
The company is studying the efficacy and safety of the gonadotropin releasing hormone agonist, analogue triptorelin pamoate six-month formulation, in the treatment of children suffering from central (GnRH-dependent) precocious puberty.
Three slow-release formulations (one, three and six months) of triptorelin pamoate has been developed.